A Multi-center Study to Evaluate the Pharmacokinetics of Diacerein and Rhein and the Safety of Diacerein After Maximum Use, Topical Administration of CCP-020 (Diacerein 1% Ointment) to Patients With Epidermolysis Bullosa (EB)
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2019
At a glance
- Drugs Diacerein (Primary)
- Indications Epidermolysis bullosa
- Focus Pharmacokinetics
- Sponsors Castle Creek Pharmaceuticals
- 06 Feb 2019 Planned End Date changed from 1 Jan 2019 to 15 Apr 2019.
- 06 Feb 2019 Planned primary completion date changed from 1 Jan 2019 to 15 Mar 2019.
- 10 May 2018 Status changed from not yet recruiting to recruiting.